Cerebral amyloid angiopathy
MONDO:0005620Hereditary cerebral hemorrhage with amyloidosis (HCHWA) describes a group of rare familial central nervous system disorders characterized by amyloid deposition in the cerebral blood vessels leading to hemorrhagic and non-hemorrhagic strokes, focal neurological deficits, and progressive cognitive decline eventually leading to dementia.
Also known as: HCHWA, dutch hereditary cerebral amyloid angiopathy, hereditary cerebral haemorrhage with amyloidosis - Dutch type, hereditary cerebral hemorrhage with amyloidosis - Dutch type, CAA, familial, cerebral amyloid angiopathy, familial, cerebral amyloid angiopathy, genetic
30 clinical trials for this condition and its sub-types, 16 tagged with Cerebral amyloid angiopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Cerebral amyloid angiopathy
-
ACys amyloidosis 1 trial
-
Cerebral amyloid angiopathy, APP-related 0 trials · 1 incl. sub-types
6 sub-types
- ABeta amyloidosis, dutch type 1 trial
- ABeta amyloidosis, Arctic type 0 trials
- ABeta amyloidosis, Iowa type 0 trials
- ABeta amyloidosis, Italian type 0 trials
- ABetaA21G amyloidosis 0 trials
- ABetaL34V amyloidosis 0 trials
-
ABri amyloidosis 0 trials
-
ADan amyloidosis 0 trials
-
New drug aims to stop brain bleeds in rare disease
Disease control OngoingThis study tests an experimental drug called ALN-APP in 200 adults with cerebral amyloid angiopathy (CAA), a condition that causes bleeding in the brain. The drug is given via spinal injection and aims to slow disease progression and reduce new brain bleeds. Participants will be …
Phase 2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Experimental drug aims to curb brain bleeds in rare genetic disease
Disease control OngoingThis study tests an experimental drug, NPI-001 (AT-001), in people with hereditary cystatin C amyloid angiopathy (HCCAA), a rare genetic condition that causes repeated brain bleeding and stroke. The trial includes about 15 participants aged 12 and older who carry the specific L68…
Phase 2 • Sponsor: Arctic Therapeutics • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can deep sleep or nerve stimulation flush toxic proteins from the brain?
Disease control By invitation onlyThis Phase 2 trial tests whether a sleep-deepening drug (lower-sodium oxybate) or a nerve-stimulating device (non-invasive vagus nerve stimulation), or both, can help clear amyloid-beta protein from the brain in people with cerebral amyloid angiopathy (CAA). Sixty participants wi…
Phase 2 • Sponsor: Leiden University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Monthly MRI reveals hidden brain bleeding patterns in elderly
Knowledge-focused OngoingThis study uses monthly MRI scans to closely watch brain changes in 75 people with cerebral amyloid angiopathy (CAA), a condition common in older adults that can cause bleeding and strokes. Researchers aim to understand how small bleeds and silent strokes develop over time. Parti…
Sponsor: Martin Dichgans • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:35 UTC